ChromaDex (NASDAQ:CDXC) Releases Earnings Results, Beats Estimates By $0.01 EPS

ChromaDex (NASDAQ:CDXC) announced its quarterly earnings results on Tuesday. The company reported $0.03 EPS for the quarter, topping analysts’ consensus estimates of $0.02 by $0.01, Zacks reports. ChromaDex had a return on equity of 4.85% and a net margin of 1.62%.

ChromaDex Trading Up 1.8 %

NASDAQ:CDXC traded up $0.10 during mid-day trading on Tuesday, reaching $5.60. The company’s stock had a trading volume of 1,110,153 shares, compared to its average volume of 387,346. The firm’s fifty day moving average price is $5.62 and its two-hundred day moving average price is $5.09. The stock has a market cap of $427.74 million, a P/E ratio of 560.56 and a beta of 2.21. ChromaDex has a 12-month low of $1.57 and a 12-month high of $7.97.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on CDXC. Roth Mkm increased their target price on shares of ChromaDex from $6.00 to $8.00 and gave the stock a “buy” rating in a report on Wednesday, November 6th. StockNews.com raised shares of ChromaDex from a “buy” rating to a “strong-buy” rating in a research note on Monday, February 24th. Finally, HC Wainwright increased their target price on ChromaDex from $6.00 to $8.00 and gave the stock a “buy” rating in a research note on Monday, November 4th.

Insider Transactions at ChromaDex

In other ChromaDex news, Director Frank L. Jaksch, Jr. sold 37,161 shares of the business’s stock in a transaction dated Friday, December 13th. The stock was sold at an average price of $6.19, for a total transaction of $230,026.59. Following the completion of the sale, the director now directly owns 244,179 shares in the company, valued at $1,511,468.01. The trade was a 13.21 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Company insiders own 9.64% of the company’s stock.

About ChromaDex

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.